TENX — TENAX THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 34956 ·
Last close
$1.42
Market Cap
$64.66M
52W High
$19.40
52W Low
$1.31
ADV30
1,774,443
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 0 | — | -18,784,000 | -17,803,000 | 121,663,000 | 117,976,000 | 8,073,000 |
| Mar 2026 | 0 | — | -16,573,000 | -15,716,000 | 123,178,000 | 118,755,000 | 8,486,000 |
| Dec 2025 | 0 | — | -16,449,000 | -15,540,000 | 104,227,000 | 97,565,000 | 7,156,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-46,029,000
Investing CF
$0
Financing CF
$58,543,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.41
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-400,973,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-66,701,000
Pretax Income TTM
$-64,863,000
Interest Exp TTM
$0
Analysts
7
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -56,385,000 | -52,599,000 | 104,227,000 | 7,156,000 | 97,071,000 | -35,800,000 |
| Dec 2024 | 0 | -19,494,000 | -17,602,000 | 96,686,000 | 4,693,000 | 91,993,000 | -14,811,000 |
| Dec 2023 | 0 | -8,234,000 | -7,711,000 | 11,685,000 | 3,587,000 | 8,098,000 | -5,904,000 |
| Dec 2022 | 0 | -11,052,643 | -11,047,895 | 3,404,709 | 1,911,968 | 1,492,741 | -11,388,571 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-64,863,000
OpCashFlow TTM
—
Assets (Latest)
$121,663,000
Forward EPS
$-1.50
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RANI | Rani Therapeutics Holdings, Inc. | $64.61M | $0.56 | — |
| KALA | KALA BIO, Inc. | $66.34M | $3.43 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $62.03M | $3.01 | — |
| GOSS | Gossamer Bio, Inc. | $67.52M | $11.04 | — |
| ACRV | Acrivon Therapeutics, Inc. | $61.28M | $1.43 | — |
News headlines (Yahoo Finance, 1h cache)
Why Is Tencent Music Entertainment Stock Falling 3.1% in Pre-Market Trading?
2026-11-17 11:46 · Yahoo
Tenax Therapeutics: Q3 Earnings Snapshot
2026-11-05 12:22 · Yahoo
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 12:00 · Yahoo
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?
2026-09-04 22:26 · Yahoo
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
2026-09-01 11:00 · Yahoo
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
2026-08-29 12:21 · Yahoo
Tenax Therapeutics’ stock crashes on Phase III trial failure
2026-08-11 11:15 · Yahoo
Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103
2026-08-10 15:03 · Yahoo
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-31 11:00 · Yahoo
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.